ONCOLOGY Vol 36, Issue 1

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, anticipates how COVID-19 will continue to impact the oncology field.

This review article discusses which frontline treatment are best for diffuse large B-cell lymphoma.

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.

Although female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.

“If we can understand the mechanisms of resistance to be able to monitor [patients] in real time, then we will be able to turn many cases of cancer into chronic diseases.”

In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.

This issues Publisher's Note focuses on a manuscript regarding gender equity on oncology guideline panels.